Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep Apnoea
Exit interviews and clinical results reinforce strong potential for meaningful improvements in sleep quality, cognitive function, and daily life Exit interviews and clinical results reinforce stro...
What are the risks that the Phase 2 data may not be replicated in larger, pivotal trials?
How could this news influence analyst coverage, target price revisions, and institutional sentiment toward ICAN?
What is the size of the target market for IHL-42X and the realistic market share the company can capture?
17 days ago